Vicept Therapeutics completes $16M Series A round
Vicept Therapeutics Inc., a developer of topical treatments for skin disorders, has completed a $16 million Series A round of funding. The Malvern, Penn. company plans to use the cash to fund Phase 1 and 2 development of V-101, the company’s lead product for the treatment of rosacea, a chronic skin condition that causes redness […]
